603998.SH
方盛制药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 9.70
−2.32%Year over year
Reported trailing growth
- Revenue
- +1.9%
- EBITDA
- —
- EBIT
- +18.6%
- EPS
- +10.8%
- Free cash flow
- +237.3%
- Operating cash flow
- +160.6%
Forward estimates
Based on analyst estimates
- Revenue
- -74.2%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -0.9%
- EBITDA
- +2.5%
- EBIT
- +2.6%
- Net income
- +2.3%
- EPS
- +2.0%
- Free cash flow
- +29.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026